Potentially huge legal issues are hovering over Kenvue. But Kimberly-Clark, which agreed to buy it for $40 billion, appears to think they’re manageable.

Kimberly-Clark is buying Kenvue, the maker of Tylenol, after months of controversy around whether the medicine is linked to autism.

Clark announced Monday it will buy Tylenol’s parent company Kenvue in a nearly $50 billion deal, creating a massive consumer products conglomerate. The merger is the latest in a recent dealmaking explosion,

Not long after President Trump made his statement, Kenvue and Johnson & Johnson got into another complicated legal mess when the Republican state of Texas sued them. The complaint says that the companies didn’t tell people about the possible risks of taking acetaminophen while pregnant.

President Trump's health secretary said Tylenol should be used with caution during pregnancy, but solid data linking it to autism is lacking.

Even though Kenvue's stock was already in a tailspin before the FDA warned pregnant woman that Tylenol posed a health risk, there are still some lingering impacts to consider.